review · Clinical Diabetes and Endocrinology
Metabolic dysfunction-associated steatotic liver disease is a common chronic condition marked by excessive liver fat accumulation, which can progress to severe liver damage and heightened morbidity. The condition is closely linked to metabolic syndrome and arises from complex interactions involving obesity, insulin resistance, and dyslipidaemia, alongside influences from genetics, diet, and gut microbiota imbalances. Beyond direct liver complications, the disease presents wider metabolic risks, including cardiovascular disease and specific cancers. While standard evaluation relies on histology and imaging, non-invasive diagnostic alternatives are increasingly preferred. Recent developments incorporate emerging biomarkers, omic technologies, and artificial intelligence, though practical challenges persist. Effective clinical management currently focuses on lifestyle modifications, precision medicine, and novel pharmacological therapies targeting underlying metabolic drivers to improve overall patient health outcomes.
Metabolic dysfunction-associated steatotic liver disease represents an escalating public health issue driven by rising rates of obesity and metabolic syndrome. Because the condition can progress silently from fat accumulation to severe liver damage, heart disease, and cancer, advancing non-invasive detection methods and targeted therapies is vital for catching disease early and preventing life-threatening complications.
The findings point towards commercial opportunities in non-invasive diagnostic tests, artificial intelligence diagnostic software, and targeted therapeutics for healthcare providers treating metabolic liver disorders. While standard imaging and lifestyle interventions are established in practice, omic tools, emerging biomarkers, and precision pharmacological therapies remain in early to intermediate development stages, facing practical adoption barriers before routine clinical deployment.
AI-generated from the published abstract. Always read the original work before citing.
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health concern and the risk of its development is connected with the increasing prevalence of metabolic syndrome (MetS) which occurs as a result of some complex obesity-induced metabolic changes. It is a common chronic liver disease characterized by excessive fat accumulation in the liver, the tendency to progress to more severe forms, and a corresponding increase in morbidity and mortality. Thus, effectively addressing the rising burden of the disease requires a thorough understanding of its complex interrelationship with obesity and MetS. MAIN BODY: MASLD results from complex interactions involving obesity, insulin resistance, and dyslipidaemia, leading to hepatic lipid accumulation, and is influenced by several genetic and environmental factors such as diet and gut microbiota dysbiosis. It has extensive metabolic and non-metabolic implications, including links to MetS components like hyperglycaemia, hypertension, and dyslipidaemia, and progresses to significant liver damage and other extra-hepatic risks like cardiovascular disease and certain cancers. Diagnosis often relies on imaging and histology, with non-invasive methods preferred over liver biopsies. Emerging biomarkers and OMIC technologies offer improved diagnostic capabilities but face practical challenges. Advancements in artificial intelligence (AI), lifestyle interventions, and pharmacological treatments show promise, with future efforts focusing on precision medicine and novel diagnostic tools to improve patient outcome. CONCLUSION: Understanding the pathogenic mechanisms underlying the development of MASLD within the context of metabolic syndrome (MetS) is essential for identifying potential therapeutic targets. Advancements in non-invasive diagnostic tools and novel pharmacological treatments, hold promise for improving the management of MASLD. Future research should focus on precision medicine and innovative therapies to effectively address the disease and its consequences.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s40842-024-00187-4
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
